Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
Profusa (NASDAQ:PFSA), a commercial stage digital health company, has completed its business combination with NorthView Acquisition Corp (NVAC). The company's common stock will begin trading on Nasdaq under the ticker "PFSA" on July 14, 2025.
The combined company secured $9 million through a secured convertible promissory note from an institutional investor, with potential access to up to $20 million under the convertible note facility. The funds will support transaction costs and working capital needs.
Profusa specializes in tissue-integrating biosensors that can monitor body chemistry continuously, transmitting data to smartphone applications and utilizing AI technologies for health management, particularly focusing on conditions like diabetes, critical limb ischemia, and peripheral arterial disease.
Profusa (NASDAQ:PFSA), azienda digitale nel settore sanitario in fase commerciale, ha completato la sua fusione con NorthView Acquisition Corp (NVAC). Le azioni ordinarie della società inizieranno a essere quotate su Nasdaq con il simbolo "PFSA" il 14 luglio 2025.
La società risultante ha ottenuto 9 milioni di dollari tramite una nota convertibile garantita da un investitore istituzionale, con la possibilità di accedere fino a 20 milioni di dollari attraverso questa linea di credito convertibile. I fondi saranno utilizzati per coprire i costi della transazione e le necessità di capitale circolante.
Profusa è specializzata in biosensori integrati nei tessuti che monitorano continuamente la chimica corporea, trasmettendo i dati alle applicazioni per smartphone e utilizzando tecnologie di intelligenza artificiale per la gestione della salute, con particolare attenzione a patologie come il diabete, l’ischemia critica degli arti e la malattia arteriosa periferica.
Profusa (NASDAQ:PFSA), una empresa de salud digital en etapa comercial, ha completado su combinación de negocios con NorthView Acquisition Corp (NVAC). Las acciones comunes de la compañía comenzarán a cotizar en Nasdaq bajo el símbolo "PFSA" el 14 de julio de 2025.
La empresa combinada aseguró 9 millones de dólares mediante una nota convertible garantizada de un inversor institucional, con acceso potencial a hasta 20 millones de dólares bajo la facilidad de la nota convertible. Los fondos apoyarán los costos de la transacción y las necesidades de capital de trabajo.
Profusa se especializa en biosensores integrados en tejidos que pueden monitorear continuamente la química corporal, transmitiendo datos a aplicaciones para smartphones y utilizando tecnologías de inteligencia artificial para la gestión de la salud, enfocándose especialmente en condiciones como la diabetes, isquemia crítica de las extremidades y enfermedad arterial periférica.
Profusa (NASDAQ:PFSA)는 상업 단계의 디지털 헬스 기업으로, NorthView Acquisition Corp (NVAC)와의 기업 합병을 완료했습니다. 회사의 보통주는 2025년 7월 14일부터 나스닥에서 "PFSA"라는 티커로 거래를 시작할 예정입니다.
합병된 회사는 기관 투자자로부터 담보부 전환 사채 형태로 900만 달러를 확보했으며, 전환 사채 시설을 통해 최대 2,000만 달러까지 추가 자금 조달이 가능합니다. 이 자금은 거래 비용과 운전자본 필요를 지원하는 데 사용됩니다.
Profusa는 조직에 통합되는 바이오센서를 전문으로 하며, 신체 화학 상태를 지속적으로 모니터링하고 스마트폰 애플리케이션으로 데이터를 전송하며, 인공지능 기술을 활용해 당뇨병, 중증 하지 허혈, 말초 동맥 질환과 같은 질환 관리에 중점을 둡니다.
Profusa (NASDAQ:PFSA), une entreprise de santé numérique en phase commerciale, a finalisé sa fusion avec NorthView Acquisition Corp (NVAC). Les actions ordinaires de la société commenceront à être cotées sur le Nasdaq sous le symbole "PFSA" le 14 juillet 2025.
La société fusionnée a obtenu 9 millions de dollars via une note convertible garantie d'un investisseur institutionnel, avec un accès potentiel allant jusqu'à 20 millions de dollars dans le cadre de cette facilité de note convertible. Ces fonds serviront à couvrir les coûts de la transaction et les besoins en fonds de roulement.
Profusa est spécialisée dans les biosenseurs intégrés aux tissus qui peuvent surveiller en continu la chimie corporelle, transmettre les données aux applications smartphone et utiliser des technologies d'intelligence artificielle pour la gestion de la santé, en se concentrant particulièrement sur des affections telles que le diabète, l'ischémie critique des membres et la maladie artérielle périphérique.
Profusa (NASDAQ:PFSA), ein Digital-Health-Unternehmen in der kommerziellen Phase, hat seine Unternehmenszusammenführung mit NorthView Acquisition Corp (NVAC) abgeschlossen. Die Stammaktien des Unternehmens werden ab dem 14. Juli 2025 unter dem Ticker "PFSA" an der Nasdaq gehandelt.
Das fusionierte Unternehmen sicherte sich 9 Millionen US-Dollar durch eine besicherte wandelbare Schuldverschreibung von einem institutionellen Investor, mit der Möglichkeit, bis zu 20 Millionen US-Dollar im Rahmen der Wandelanleihe zu erhalten. Die Mittel werden zur Deckung der Transaktionskosten und des Betriebskapitals verwendet.
Profusa ist auf gewebsintegrierte Biosensoren spezialisiert, die kontinuierlich die Körperchemie überwachen, Daten an Smartphone-Anwendungen übertragen und KI-Technologien zur Gesundheitsverwaltung einsetzen, wobei der Fokus insbesondere auf Erkrankungen wie Diabetes, kritischer Gliedmaßenischämie und peripherer arterieller Verschlusskrankheit liegt.
- None.
- Warrants will trade on OTCID market instead of Nasdaq, potentially limiting liquidity
- Additional debt through convertible note could lead to future dilution
- Post-SPAC merger companies often face market volatility and scrutiny
Insights
Profusa completes SPAC merger with NorthView, raises $9M initial funding, and begins Nasdaq trading July 14 under PFSA ticker.
Profusa has successfully completed its business combination with NorthView Acquisition Corp (NVAC), a special purpose acquisition company (SPAC), with trading on Nasdaq under ticker PFSA set to commence on July 14, 2025. This transition to public markets represents a significant milestone for the commercial-stage digital health company that specializes in continuous biochemical monitoring technology.
The transaction structure includes notable financial components. Profusa has secured
Profusa's core technology focuses on tissue-integrating biosensors designed to function for months at a time, continuously monitoring and transmitting biochemical data to smartphone applications. The company is targeting applications in both general health monitoring and management of specific conditions including diabetes, critical limb ischemia (CLI), and peripheral arterial disease (PAD).
This public market debut comes after a decade-long development journey. The transaction transforms Profusa's capital structure and potential market visibility, while the company's warrants will continue trading on the OTCID market rather than Nasdaq. For investors, this represents early access to a commercial-stage company in the growing digital health monitoring space, with technology that integrates biochemical sensing, mobile applications, and AI-powered analytics.
Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA"
BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced the closing of its business combination with NorthView Acquisition Corp. (“NVAC”), a special purpose acquisition company, which was approved by NVAC’s shareholders on June 9, 2025. The combined company will operate under the name Profusa, Inc., with its common stock expected to begin trading on Nasdaq under the ticker symbol “PFSA”, beginning on July 14, 2025. The Company’s warrants will not trade on Nasdaq but rather will continue to trade on the OTCID market.
“In a journey that began over a decade ago, driven by a mission to harness transformative science to positively impact quality of daily living and chronic disease management, we are excited to mark a key milestone of going public and trading on Nasdaq. We believe being a public company better positions us to advance our vision in pioneering tissue-integrating biosensors platform that could function for months at a time, with transformative lower costs, and continuously monitor and transmit body chemistries to smart phone applications, and leveraging the best-in-class data analytics and AI technologies, allowing users and healthcare professionals to make real-time actionable decisions that improve general health or manage a chronic disease such as diabetes or critical limb ischemia (CLI), and peripheral arterial disease (PAD),” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “Thanks to the support of our dedicated employees, partners and investors for leading us to this exciting moment in our company’s history.”
In connection with the business combination, the combined company has also issued a secured convertible promissory note to an institutional investor, raising
Advisors
A.G.P./Alliance Global Partners, I-Bankers Securities and Dawson James Securities acted as financial advisor to NVAC. Ellenoff Grossman & Schole LLP acted as legal advisor to Profusa. ArentFox Schiff LLP acted as legal advisor to NorthView Acquisition Corp. and Lucosky Brookman LLP acted as legal advisor to the institutional investor in connection with the secured convertible promissory note issued by the combined company.
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and described in other documents filed by NVAC or Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
Profusa: brets@coreir.com
FAQ
When will Profusa (PFSA) start trading on Nasdaq?
How much funding did Profusa secure in connection with the SPAC merger?
What is Profusa's main business focus?
Who were the advisors for Profusa's SPAC merger?
What happens to Profusa's warrants after the SPAC merger?
